{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T02:41:42Z","timestamp":1792377702008,"version":"4.4.0"},"reference-count":34,"publisher":"Tsinghua University Press","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sarcopenia is a progressive age-related skeletal muscle disorder characterized by the loss of muscle mass, strength, and physical performance. Increasing evidence suggests that activation of the renin\u2013angiotensin system (RAS) contributes to muscle wasting through promotion of protein degradation and impairment of anabolic signaling. Azilsartan (AZL), a highly selective angiotensin II type 1 receptor (AT1R) blocker, has demonstrated pleiotropic effects beyond blood pressure control. However, its effects on skeletal muscle atrophy and the underlying mechanisms remain incompletely understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We combined a prospective observational study with mechanistic investigations in animal and cellular models. Older adults with hypertension and sarcopenia received AZL (40 mg\/day) or other antihypertensive therapies for 6 months, and muscle strength, gait speed, and appendicular skeletal muscle mass were assessed. Moreover, Ang II-induced skeletal muscle atrophy models were established in mice and C2C12 myotubes to evaluate the effects of AZL on muscle morphology and signaling pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>AZL treatment was associated with significant improvements in handgrip strength, gait speed, and appendicular skeletal muscle mass in older hypertensive patients. In experimental models, Ang II induced skeletal muscle dysfunction and atrophy, characterized by reduced exercise capacity, decreased grip strength, and muscle fiber loss, were attenuated by AZL treatment. Mechanistically, AZL restored PI3K\/Akt\/FOXO3a signaling and suppressed the expression of the muscle-specific ubiquitin ligases Atrogin-1 and MuRF1. The protective effects of AZL were abolished by the AT1R agonist TRV120027 in both in vivo and in vitro models and were further attenuated by the PI3K inhibitor LY294002 in C2C12 myotubes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>AZL attenuates Ang II-induced skeletal muscle atrophy through AT1R blockade and subsequent activation of PI3K\/Akt\/FOXO3a signaling, thereby suppressing ubiquitin-proteasome system-mediated muscle protein degradation. These findings provide mechanistic and translational evidence supporting the potential of AZL as a therapeutic strategy for preserving skeletal muscle health in older adults with hypertension.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.26599\/1671-5411.2026.09.008","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T02:39:01Z","timestamp":1792377541000},"page":"609-621","source":"Crossref","is-referenced-by-count":0,"title":["Azilsartan ameliorates angiotensin II-induced skeletal muscle atrophy via AT1R-mediated PI3K\/AKT\/FOXO3a signaling pathway"],"prefix":"10.26599","volume":"23","author":[{"given":"Yan","family":"CUI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Peng","family":"LI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"YU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"LU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Wen","family":"LI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"ZHAO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Shui","family":"XU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Kai","family":"SHEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"LU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"GAO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11138","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/jcsm.12783","article-title":"Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis","volume":"13","author":"F Petermann-Rocha","year":"2022","unstructured":"F Petermann-Rocha. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. 2022, 13: 86-99.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"101270","DOI":"10.1016\/j.mam.2024.101270","article-title":"Frontiers in sarcopenia: Advancements in diagnostics, molecular mechanisms, and therapeutic strategies","volume":"97","author":"D Liu","year":"2024","unstructured":"D Liu. Frontiers in sarcopenia: Advancements in diagnostics, molecular mechanisms, and therapeutic strategies. 2024, 97: 101270.","journal-title":"Mol Aspects Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/med.21343","article-title":"Renin-angiotensin system: an old player with novel functions in skeletal muscle","volume":"35","author":"C Cabello-Verrugio","year":"2015","unstructured":"C Cabello-Verrugio. Renin-angiotensin system: an old player with novel functions in skeletal muscle. 2015, 35: 437-463.","journal-title":"Med Res Rev"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1007\/s11010-024-05043-8","article-title":"Renin angiotensin system-induced muscle wasting: putative mechanisms and implications for clinicians.","volume":"480","author":"B Afsar","year":"2025","unstructured":"B Afsar. Renin angiotensin system-induced muscle wasting: putative mechanisms and implications for clinicians.. 2025, 480: 1935-1949.","journal-title":"Mol Cell Biochem"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.3390\/antiox10101561","article-title":"Dieckol Reduces Muscle Atrophy by Modulating Angiotensin Type II Type 1 Receptor and NADPH Oxidase in Spontaneously Hypertensive Rats","volume":"10","author":"S Oh","year":"2021","unstructured":"S Oh. Dieckol Reduces Muscle Atrophy by Modulating Angiotensin Type II Type 1 Receptor and NADPH Oxidase in Spontaneously Hypertensive Rats. 2021, 10: 1561.","journal-title":"Antioxidants (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41598-023-27737-7","article-title":"Angiotensin II type 1a receptor deficiency alleviates muscle atrophy after denervation","volume":"13","author":"S Takayama","year":"2023","unstructured":"S Takayama. Angiotensin II type 1a receptor deficiency alleviates muscle atrophy after denervation. 2023, 13: 519.","journal-title":"Sci Rep"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1161\/CIRCRESAHA.114.305393","article-title":"Angiotensin II induces Skeletal Muscle Atrophy by Activating TFEB-Mediated MuRF1 Expression.","volume":"117","author":"P Du Bois","year":"2015","unstructured":"P Du Bois. Angiotensin II induces Skeletal Muscle Atrophy by Activating TFEB-Mediated MuRF1 Expression.. 2015, 117: 424-436.","journal-title":"Circ Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.canlet.2005.02.007","article-title":"Angiotensin II directly inhibits protein synthesis in murine myotubes","volume":"231","author":"ST Russell","year":"2006","unstructured":"ST Russell. Angiotensin II directly inhibits protein synthesis in murine myotubes. 2006, 231: 290-294.","journal-title":"Cancer Lett"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1152\/japplphysiol.00731.2025","article-title":"Sex-specific protective effects of angiotensin II type 1 receptor knockdown on disuse muscle atrophy in the rat soleus muscle","volume":"139","author":"T Yoshihara","year":"2025","unstructured":"T Yoshihara. Sex-specific protective effects of angiotensin II type 1 receptor knockdown on disuse muscle atrophy in the rat soleus muscle. 2025, 139: 1125-1138.","journal-title":"J Appl Physiol (1985)"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.clinthera.2011.10.007","article-title":"Azilsartan medoxomil: a new Angiotensin receptor blocker","volume":"33","author":"K Zaiken","year":"2011","unstructured":"K Zaiken. Azilsartan medoxomil: a new Angiotensin receptor blocker. 2011, 33: 1577-1589.","journal-title":"Clin Ther"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1021\/acsomega.0c03655","article-title":"Azilsartan Suppressed LPS-Induced Inflammation in U937 Macrophages through Suppressing Oxidative Stress and Inhibiting the TLR2\/MyD88 Signal Pathway","volume":"6","author":"Q Dong","year":"2021","unstructured":"Q Dong. Azilsartan Suppressed LPS-Induced Inflammation in U937 Macrophages through Suppressing Oxidative Stress and Inhibiting the TLR2\/MyD88 Signal Pathway. 2021, 6: 113-118.","journal-title":"ACS Omega"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-023-04083-8","author":"","unstructured":"","journal-title":"null"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1093\/jpp\/rgab097","article-title":"Azilsartan ameliorates ventricular hypertrophy in rats suffering from pressure overload-induced cardiac hypertrophy by activating the Keap1-Nrf2 signalling pathway","volume":"73","author":"N Hou","year":"2021","unstructured":"N Hou. Azilsartan ameliorates ventricular hypertrophy in rats suffering from pressure overload-induced cardiac hypertrophy by activating the Keap1-Nrf2 signalling pathway. 2021, 73: 1715-1725.","journal-title":"J Pharm Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10557-019-06900-1","article-title":"Angiotensin II Type 1 Receptor Antagonist Azilsartan Restores Vascular Reactivity Through a Perivascular Adipose Tissue-Independent Mechanism in Rats with Metabolic Syndrome","volume":"33","author":"S Kagota","year":"2019","unstructured":"S Kagota. Angiotensin II Type 1 Receptor Antagonist Azilsartan Restores Vascular Reactivity Through a Perivascular Adipose Tissue-Independent Mechanism in Rats with Metabolic Syndrome. 2019, 33: 501-509.","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"105025","DOI":"10.1016\/j.archger.2023.105025","article-title":"Azilsartan Ameliorates Skeletal Muscle Wasting in High Fat Diet (HFD)-induced Sarcopenic Obesity in Rats via Activating Akt Signalling Pathway","volume":"112","author":"P Prajapati","year":"2023","unstructured":"P Prajapati. Azilsartan Ameliorates Skeletal Muscle Wasting in High Fat Diet (HFD)-induced Sarcopenic Obesity in Rats via Activating Akt Signalling Pathway. 2023, 112: 105025.","journal-title":"Arch Gerontol Geriatr"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.26599\/1671-5411.2025.01.008","article-title":"Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision)","volume":"22","author":"JG Wang","year":"2025","unstructured":"JG Wang. Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision). 2025, 22: 1-149.","journal-title":"J Geriatr Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jamda.2019.12.012","article-title":"Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment","volume":"21","author":"LK Chen","year":"2020","unstructured":"LK Chen. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. 2020, 21: 300-307 e302.","journal-title":"J Am Med Dir Assoc"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3945\/ajcn.112.037853","article-title":"Malnutrition self-screening by using MUST in hospital outpatients: validity, reliability, and ease of use","volume":"96","author":"AL Cawood","year":"2012","unstructured":"AL Cawood. Malnutrition self-screening by using MUST in hospital outpatients: validity, reliability, and ease of use. 2012, 96: 1000-1007.","journal-title":"Am J Clin Nutr"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"117593","DOI":"10.1016\/j.lfs.2020.117593","article-title":"Branched-chain amino acid supplementation ameliorates angiotensin II-induced skeletal muscle atrophy","volume":"250","author":"K Yamanashi","year":"2020","unstructured":"K Yamanashi. Branched-chain amino acid supplementation ameliorates angiotensin II-induced skeletal muscle atrophy. 2020, 250: 117593.","journal-title":"Life Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1113\/expphysiol.2014.084095","article-title":"Angiotensin II can directly induce mitochondrial dysfunction, decrease oxidative fibre number and induce atrophy in mouse hindlimb skeletal muscle","volume":"100","author":"T Kadoguchi","year":"2015","unstructured":"T Kadoguchi. Angiotensin II can directly induce mitochondrial dysfunction, decrease oxidative fibre number and induce atrophy in mouse hindlimb skeletal muscle. 2015, 100: 312-322.","journal-title":"Exp Physiol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1186\/s12967-026-08051-y","article-title":"Paraxanthine and azilsartan attenuate gentamicin-induced renal fibrosis via modulation of TGF-beta1\/Smad3\/7 signaling and miRNA-21\/miRNA-200b expression","volume":"24","author":"NS Rizk El-Adwy","year":"2026","unstructured":"NS Rizk El-Adwy. Paraxanthine and azilsartan attenuate gentamicin-induced renal fibrosis via modulation of TGF-beta1\/Smad3\/7 signaling and miRNA-21\/miRNA-200b expression. 2026, 24: 684.","journal-title":"J Transl Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"82ra37","DOI":"10.1126\/scitranslmed.3002227","article-title":"Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia","volume":"3","author":"TN Burks","year":"2011","unstructured":"TN Burks. Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. 2011, 3: 82ra37.","journal-title":"Sci Transl Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"175223","DOI":"10.1016\/j.ejphar.2022.175223","article-title":"Effect of losartan treatment on Smad signaling and recovery from hindlimb unloading-induced soleus muscle atrophy in female rats","volume":"931","author":"T Yoshihara","year":"2022","unstructured":"T Yoshihara. Effect of losartan treatment on Smad signaling and recovery from hindlimb unloading-induced soleus muscle atrophy in female rats. 2022, 931: 175223.","journal-title":"Eur J Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"14453","DOI":"10.1038\/srep14453","article-title":"Angiotensin II receptor blockade promotes repair of skeletal muscle through down-regulation of aging-promoting C1q expression","volume":"5","author":"C Yabumoto","year":"2015","unstructured":"C Yabumoto. Angiotensin II receptor blockade promotes repair of skeletal muscle through down-regulation of aging-promoting C1q expression. 2015, 5: 14453.","journal-title":"Sci Rep"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"111458","DOI":"10.1016\/j.cellsig.2024.111458","article-title":"Inhibition of TREM-1 ameliorates angiotensin II-induced atrial fibrillation by attenuating macrophage infiltration and inflammation through the PI3K\/AKT\/FoxO3a signaling pathway","volume":"124","author":"X Chen","year":"2024","unstructured":"X Chen. Inhibition of TREM-1 ameliorates angiotensin II-induced atrial fibrillation by attenuating macrophage infiltration and inflammation through the PI3K\/AKT\/FoxO3a signaling pathway. 2024, 124: 111458.","journal-title":"Cell Signal"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"119504","DOI":"10.1016\/j.biopha.2026.119504","article-title":"Dysregulation of the ubiquitin-proteasome system in aging skeletal muscle","volume":"199","author":"G Song","year":"2026","unstructured":"G Song. Dysregulation of the ubiquitin-proteasome system in aging skeletal muscle. 2026, 199: 119504.","journal-title":"Biomed Pharmacother"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"105807","DOI":"10.1016\/j.phrs.2021.105807","article-title":"Skeletal muscle atrophy: From mechanisms to treatments","volume":"172","author":"L Yin","year":"2021","unstructured":"L Yin. Skeletal muscle atrophy: From mechanisms to treatments. 2021, 172: 105807.","journal-title":"Pharmacol Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2020.07.015","author":"","unstructured":"","journal-title":"null"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s11658-024-00572-y","article-title":"The role of mitochondrial dynamics and mitophagy in skeletal muscle atrophy: from molecular mechanisms to therapeutic insights","volume":"29","author":"Y Lei","year":"2024","unstructured":"Y Lei. The role of mitochondrial dynamics and mitophagy in skeletal muscle atrophy: from molecular mechanisms to therapeutic insights. 2024, 29: 59.","journal-title":"Cell Mol Biol Lett"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1007\/s40279-024-02072-7","article-title":"Mitochondria as nutritional targets to maintain muscle health and physical function during ageing","volume":"54","author":"SC Broome","year":"2024","unstructured":"SC Broome. Mitochondria as nutritional targets to maintain muscle health and physical function during ageing. 2024, 54: 2291-2309.","journal-title":"Sports Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.tips.2023.07.006","article-title":"Muscle wasting: emerging pathways and potential drug targets","volume":"44","author":"A Domaniku","year":"2023","unstructured":"A Domaniku. Muscle wasting: emerging pathways and potential drug targets. 2023, 44: 705-718.","journal-title":"Trends Pharmacol Sci"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/cells14040244","article-title":"Withaferin A attenuates muscle cachexia induced by angiotensin ii through regulating pathways activated by angiotensin II","volume":"14","author":"SS Kakar","year":"2025","unstructured":"SS Kakar. Withaferin A attenuates muscle cachexia induced by angiotensin ii through regulating pathways activated by angiotensin II. 2025, 14: 244.","journal-title":"Cells"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1152\/japplphysiol.00898.2018","article-title":"Angiotensin II suppresses autophagy and disrupts ultrastructural morphology and function of mitochondria in mouse skeletal muscle","volume":"126","author":"KAS Silva","year":"2019","unstructured":"KAS Silva. Angiotensin II suppresses autophagy and disrupts ultrastructural morphology and function of mitochondria in mouse skeletal muscle. 2019, 126: 1550-1562.","journal-title":"J Appl Physiol (1985)"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"C634","DOI":"10.1152\/ajpcell.00372.2013","article-title":"Angiotensin II modulates mouse skeletal muscle resting conductance to chloride and potassium ions and calcium homeostasis via the AT1 receptor and NADPH oxidase","volume":"307","author":"A Cozzoli","year":"2014","unstructured":"A Cozzoli. Angiotensin II modulates mouse skeletal muscle resting conductance to chloride and potassium ions and calcium homeostasis via the AT1 receptor and NADPH oxidase. 2014, 307: C634-647.","journal-title":"Am J Physiol Cell Physiol"}],"container-title":["Journal of Geriatric Cardiology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T02:39:02Z","timestamp":1792377542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciopen.com\/article\/10.26599\/1671-5411.2026.09.008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"URL":"https:\/\/doi.org\/10.26599\/1671-5411.2026.09.008","relation":{},"ISSN":["1671-5411"],"issn-type":[{"value":"1671-5411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}